Inhibitory effect of danazol on melanogenesis in mouse B16 melanoma cells

In: Archives of Pharmacal Research · 2010 · vol. 33(12) , pp. 1959–1965 · doi:10.1007/s12272-010-1211-4 · PMID:21191761 · W2015437333
article OA: closed CC0 ⤵ 1 in-corpus citation
AI-generated summary by claude@2026-06+body, 2026-06-08

Danazol inhibits melanogenesis in B16 melanoma cells by reducing tyrosinase protein levels through post-transcriptional regulation, without affecting tyrosinase mRNA or direct enzyme activity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text

This paper screened more than 200 generic drugs for activity as potential skin-lightening agents using mouse B16 melanoma cells and found danazol inhibited melanogenesis in a dose-dependent manner (IC50 9.3 μM). The study showed danazol reduced cellular tyrosinase activity in B16 cells, while not directly inhibiting murine tyrosinase activity in a cell-free system. Western blotting indicated danazol downregulated tyrosinase protein levels, whereas RT-PCR showed it did not reduce tyrosinase mRNA, suggesting post-transcriptional regulation. The paper’s limitation is that its mechanistic evidence is confined to an in vitro melanoma cell model. Relevance to endometriosis: the references cite prior danazol treatment for pelvic endometriosis, though the paper itself focuses on melanogenesis inhibition in B16 melanoma cells.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 4,471 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

In the present study, more than 200 generic drugs were screened to verify their applicability as a skin-lightening agent using mouse B16 melanoma cells. Of the numerous agents, danazol was found to inhibit melanogenesis in B16 cells in a dose-dependent manner with an IC50 value of 9.3 μM. In addition, danazol reduced cellular tyrosinase activity in B16 cells but did not directly inhibit the murine tyrosinase activity in the cell-free system. Western blotting analysis confirmed that danazol downregulated the levels of tyrosinase protein in B16 cells, and reverse-transcription polymerase chain reaction (RT-PCR) analysis revealed that danazol did not downregulate the levels of tyrosinase mRNA in the cells. These results indicate that danazol inhibits melanogenesis in B16 cells via reducing the tyrosinase activity by post-transcriptional regulation. Similar content being viewed by others

References

Ando, H., Kondoh, H., Ichihashi, M., and Hearing, V. J., Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase. J. Invest. Dermatol., 127, 751–761 (2007). Chang, T. S., An updated review on tyrosinase inhibitors. Int. J. Mol. Sci., 10, 2440–2475 (2009). Chang, T. S., Lin, M. Y., and Lin, H. J., Identifying 8-hydroxynaringenin as a suicide substrate of mushroom tyrosinase. J. Cosmet. Sci., 61, 205–210 (2010). Crotty, B. A., Znaiden, A. P., and Johnson, A., Method and composition for skin lightening. U.S. Patent, 5858997 (Jan. 12, 1999). Ding, H. Y., Lin, H. C., and Chang, T. S., Tyrosinase inhibitors isolated from the roots of Paeonia suffruticosa. J. Cosmet. Sci., 60, 347–352 (2009). Hamilton, J. B. and Hubert G., Photographic nature of tanning of the human skin as shown by studies of male hormone therapy. Science, 88, 481 (1938). Igarashi, M., Iizuka, M., Abe, Y., and Ibuki, Y., Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis. Hum. Reprod., 13, 1952–1956 (1998). Imokawa, G., Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders. Pigment Cell Res., 17, 96–110 (2004). Kline, E. L., Carland, K. C., Warren, J. T., and Smith, T. J., Effect of testosterone on imidazole-induced tyrosinase expression in B16 melanoma cell culture. Cancer Res., 48, 3586–3590 (1988). Mun, Y. J., Lee, S. W., Jeong, H. W., Lee, K. G., Kim, J. H., and Woo, W. H., Inhibitory effect of miconazole on melanogenesis. Biol. Pharm. Bull., 27, 806–809 (2004). Neeley, E., Fritch, G., Fuller, A., Wolfe, J., Wright, J., and Flurkey, W., Variations in IC50 values with purity of mushroom tyrosinase. Int. J. Mol. Sci., 10, 3811–3823 (2009). Sato, K., Takahashi, H., Iraha, R., and Toriyama, M., Downregulation of tyrosinase expression by acetylsalicylic acid in murine B16 melanoma. Biol. Pharm. Bull., 31, 33–37 (2008). Slominski, A., Tobin, D. J., Shibahara, S., and Wortsman, J., Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev., 84, 1155–1228 (2004). Solano, F., Briganti, S., Picardo, M., and Ghanem, G., Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res., 19, 550–571 (2006). Spencer, J. D. and Schallreuter, K. U., Regulation of pigmentation in human epidermal melanocytes by functional high-affinity β-melanocyte-stimulating hormone/melanocortin-4 receptor signaling. Endocrinology, 150, 1250–1258 (2009). Tadokoro, T., Rouzaud, F., Itami, S., Hearing, V. J., and Yoshikawa, K., The inhibitory effect of androgen and sexhormone-binding globulin on the intracellular cAMP level and tyrosinase activity. Pigment Cell Res., 16, 190–197 (2003). Tai, S. S., Lin, C. G., Wu, M. H., and Chang, T. S., Evaluation of depigmenting activity by 8-hydroxydaidzein in mouse B16 melanoma cells and human volunteers. Int. J. Mol. Sci., 10, 4257–4266 (2009). Zhu, W. and Gao, J., The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. J. Investig. Dermatol. Symp. Proc., 13, 20–24 (2008). Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Chang, TS., Lin, JJ. Inhibitory effect of danazol on melanogenesis in mouse B16 melanoma cells. Arch. Pharm. Res. 33, 1959–1965 (2010). https://doi.org/10.1007/s12272-010-1211-4 Received: Revised: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s12272-010-1211-4

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Cited by (1)

References (18)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-11T06:12:37.668444+00:00
License: CC0 · commercial use OK